The International Bladder Cancer Bank: Proposal for a new study concept

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 4, 2004, Pages 277-284

  Goebell, Peter J ^a,b   Groshen, Susan ^a   Schmitz Dräger, Bernd J ^c   Sylvester, Richard ^d   Kogevinas, Manolis ^e   Malats, Núria ^e   Sauter, Guido ^f   Barton Grossman, H ^g   Waldman, Fred ^h   Cote, Richard J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c EuromedClinic ^*  (Germany)

^d EORTC DATA CENTER   (Belgium)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER CENTER; CANCER DIAGNOSIS; CANCER RESEARCH; EVALUATION; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; STATISTICAL ANALYSIS; TECHNOLOGY;

DATA COLLECTION; DATABASES, FACTUAL; HUMANS; INTERNATIONAL COOPERATION; PRACTICE GUIDELINES; PROGRAM DEVELOPMENT; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 3342893268     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00175-3     Document Type: Article

References (41)

1. Malkin A. Tumor markers. Tannock I.F., Hill R.P. The Basic Science of Oncology. 2nd ed.:1992;McGraw-Hill, New York
2. Baasiri R.A., Glasser S.R., Steffen D.L., Wheeler D.A. The breast cancer gene database a collaborative information resource. Oncogene. 18:1999;7958-7965
3. Boring C.C., Squires T.S., Tong T., Montgomery S. Cancer statistics. CA Cancer J Clin. 44:1994;7-26
4. Heney N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 19:1992;429-433
5. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer an analysis of 315 cases. J Urol. 127:1982;250-252
6. Catalona W.J. Urothelial tumors of the urinary tract. Walsh P.C., Retik A.B., Stamey T.A., Vaughan D.E. Jr. Cambell's Urology. Vol. 2:1992;1094-1158 Saunders, Philadelphia
7. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer long-term results in 1,054 patients. J Clin Oncol. 19:2001;666-675
8. Kiemeney L.A., Witjes J.A., Heijbroek R.P., Verbeek A.L., Debruyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol. 150:1993;60-64
9. Cote R.J., Chatterjee S.J. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am. 5:1999;2-15
10. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA. 76:1979;2420-2424
11. Melero J.A., Stitt D.T., Mangel W.F., Carroll R.B. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology. 93:1979;466-480
12. Oka K., Ishikawa J., Bruner J.M., Takahashi R., Saya H. Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction. Mol Carcinog. 4:1991;10-13
13. Borland R.N., Brendler C.B., Isaacs W.B. Molecular biology of bladder cancer. Hematol Oncol Clin North Am. 6:1992;31-39
14. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma a marker for disease progression. J Natl Cancer Inst. 85:1993;53-59
15. Olumi A.F., Tsai Y.C., Nichols P.W., et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50:1990;7081-7083
16. Llopis J., Alcaraz A., Ribal M.J., et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol. 37:2000;644-653
17. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1994;1259-1264
18. Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G. p53 and treatment of bladder cancer. Nature. 385:1997;123-125
19. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 6:2000;1854-1864
20. Zlotta A.R., Schulman C.C. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am. 27:2000;179-189
21. Schmitz-Dräger B.J., Goebell P.J., Ebert T., Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer a new toy for urologic scientists? Eur Urol. 38:2000;691-700
22. Malats N., Kogevinas M., Bustos A., Torà M., Real F.X. Bladder cancer and p53 an example of what should not be done in biomarker research. Int J Biol Markers. 15:2000;S30
23. Schmitz-Dräger B.J., Goebell P.J., Heydthausen M. The International Study Initiative on Bladder Cancer (ISBC). p53 Immunohistochemistry in bladder cancer: combined analysis: a way to go? Urol Oncol. 5:2000;204-215
24. Esrig D., Spruck C.H. 3rd, Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397
25. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 mutations in human bladder cancer genotypic versus phenotypic patterns. Int J Cancer. 56:1994;347-353
26. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
27. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 86:1994;829-835
28. Schmoor C., Sauerbrei W., Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med. 19:2000;441-452
29. Pajak T.F., Clark G.M., Sargent D.J., et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 124:2000;1011-1015
30. Altman D.G., Royston P. What do we mean by validating a prognostic model? Stat Med. 19:2000;453-473
31. Begg C.B., Cramer L.D., Venkatraman E.S., Rosai J. Comparing tumour staging and grading systems a case study and a review of the issues, using thymoma as a model. Stat Med. 19:2000;1997-2014
32. Simon R., Altman D.G. (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 69:1994;979-985
33. McGuire W.L. Breast cancer prognostic factors evaluation guidelines. J Natl Cancer Inst. 83:1991;154-155
34. Stockler M.R., Boyd N.F., Tannock I.F. Guide to studies of diagnostic tests, prognostic factors and treatments. Tannock I.F., Hill R.P. The Basic Science of Oncology. 3rd ed.:1998;466-492 McGraw-Hill, New York
35. Drew P.J., Ilstrup D.M., Kerin M.J., Monson J.R. Prognostic factors guidelines for investigation design and state of the art analytical methods. Surg Oncol. 7:1998;71-76
36. Grossman H.B. The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urol Oncol. 5:2000;183-184
37. Home page of the International Bladder Cancer Network (IBCN). 2003;. [Online]. http://www.uni-essen.de/urologie/ibcn/index.html (accessed 2 December)
38. Malone T., Catalano P.J., O'Dwyer P.J., Giantonio B. High rate of consent to bank biologic samples for future research the Eastern Cooperative Oncology Group experience. J Natl Cancer Inst. 94:2002;769-771
39. Schilsky R.L., Dressler L.M., Bucci D., et al. Cooperative group tissue banks as research resources the Cancer and Leukemia Group B tissue repositories. Clin Cancer Res. 8:2002;943-948
40. Kallioniemi O.P., Wagner U., Kononen J., Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:2001;657-662
41. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:1998;844-847